uso 23272
Cáncer de mama-Detección de enfermedad residual mínima/molecular y monitorización de la terapia en pacientes con TNBC en estadio temprano-Fase I (B-STRONGER-I) (01-PS-001)
Tipos de enfermedades: Investigación sobre el cáncer de mama
Requisitos de elegibilidad:
• Histologically documented TNBC (ER ≤10% by IHC, PR ≤10% by IHC and HER2 0 or
1+ by IHC or FISH ratio <2 or HER2 gene copy number of <6)
• Early-stage (stage I-III) TNBC scheduled to undergo NAC treatment with curative
intent
• Be willing to provide blood samples before and during treatment
• Have available biopsy tissue
• Pts with current or history of another primary cancer within 5 years of study entry are
excluded
• Pt that started systemic therapy for BC are excluded
• No blood transfusion within two weeks before collection of blood for central ctDNA
testing
Disponible en: